Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials

Objectives To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy of two different anti-VEGF retreatment criteria. Data sources PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched from inception to 31 July 2022. Study selection Randomised controlled trials (RCTs) comparing anti-VEGF with sham, photodynamic therapy (PDT) or PDT combination therapy in patients with myopia CNV were reviewed and selected. RCTs comparing visual acuity (VA) stabilisation or disease activity as anti-VEGF retreatment criteria were also included in the study. Data extraction and synthesis Two reviewers independently conducted data extraction and quality assessment. We used a random-effects model for all analyses. Primary outcomes included best-corrected visual acuity (BCVA) and central foveal thickness. Secondary outcomes included number of patients who gained more than three lines in BCVA, number of anti-VEGF injections and ocular adverse event (AE). Results Seven RCTs involving 1007 patients were included. Compared with sham and PDT therapy, anti-VEGF therapy achieved better BCVA gains of −0.28 logMAR (95% CI −0.36 to −0.20, p<0.00001) and −0.14 logMAR (95% CI −0.17 to −0.10, p<0.00001), respectively. Both ranibizumab and bevacizumab improved patients’ vision better than PDT therapy and no definitive increased risk of ocular AE was observed. Analysis of two small RCTs showed that PDT combination therapy had similar visual improvement and needed fewer anti-VEGF injections compared with anti-VEGF monotherapy (weighted mean difference (WMD)=1.30; 95% CI 1.24 to 1.37, p<0.00001). Anti-VEGF retreatment guided by disease activity criteria resulted in comparable visual improvement and reduced anti-VEGF injections compared with retreatment guided by VA stabilisation (WMD=0.83; 95% CI 0.42 to 1.25, p<0.0001). Conclusions Anti-VEGF therapy is effective and well-tolerated for myopia CNV patients. Anti-VEGF retreatment guided by disease activity criteria can achieve comparable efficacy and potentially reduce anti-VEGF injections. PROSPERO registration number CRD42021292806.

[1]  B. Karasu,et al.  The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization , 2022, International Ophthalmology.

[2]  T. Lai,et al.  Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization , 2021, Expert opinion on drug safety.

[3]  L. Di Antonio,et al.  Anti-VEGF Therapy in Myopic CNV. , 2021, Current Drug Targets.

[4]  T. Soomro,et al.  Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization , 2020, European journal of ophthalmology.

[5]  T. Lai,et al.  Ranibizumab for myopic choroidal neovascularization , 2020, Expert opinion on biological therapy.

[6]  E. Mayo-Wilson,et al.  PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews , 2020, BMJ.

[7]  Xiaodong Sun,et al.  Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy: a post-hoc analysis , 2019, Eye.

[8]  Haoyu Li,et al.  Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization , 2019, Medicine.

[9]  J. Jonas,et al.  IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies , 2019, Investigative ophthalmology & visual science.

[10]  C. Jin,et al.  Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12‐month results from a randomized controlled study , 2018, Clinical & experimental ophthalmology.

[11]  You-xin Chen,et al.  RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION , 2018, Retina.

[12]  P. Mitchell,et al.  Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. , 2017, Ophthalmology.

[13]  Y. Ikuno,et al.  Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia , 2017, Progress in Retinal and Eye Research.

[14]  M. Varano,et al.  FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION , 2017, Retina.

[15]  T. Lai,et al.  LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY , 2017, Retina.

[16]  C. S. Lee,et al.  CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2017, Retina.

[17]  C. Costagliola,et al.  Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.

[18]  Ting Zhang,et al.  Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. , 2016, The Cochrane database of systematic reviews.

[19]  D. Ng,et al.  FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION , 2015, Retina.

[20]  T. Wong,et al.  Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. , 2015, Ophthalmology.

[21]  T. Wong,et al.  Myopic choroidal neovascularisation: current concepts and update on clinical management , 2014, British Journal of Ophthalmology.

[22]  S. Saviano,et al.  Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A one-year follow-up controlled study. , 2014, International journal of ophthalmology.

[23]  S. Kara,et al.  Macular hole after intravitreal bevacizumab injection for choroidal neovascularisation , 2014, Clinical and experimental optometry.

[24]  T. Wong,et al.  RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. , 2014, Ophthalmology.

[25]  S. Sivaprasad,et al.  Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. , 2013, Ophthalmology.

[26]  J. Ruiz-Moreno,et al.  Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. , 2013, Ophthalmology.

[27]  You-xin Chen,et al.  INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: Systematic Review and Meta-Analysis , 2013, Retina.

[28]  M. C. Donati,et al.  LONG-TERM RESULTS OF PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION WITH PATHOLOGIC MYOPIA , 2012, Retina.

[29]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[30]  B. Kirchhof,et al.  Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography , 2011, British Journal of Ophthalmology.

[31]  P. Rosenfeld,et al.  NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS , 2010, Retina.

[32]  A. Papayannis,et al.  Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. , 2010, Archives of ophthalmology.

[33]  Eberhard Spoerl,et al.  BIOMECHANICAL SIGNIFICANCE OF THE HUMAN INTERNAL LIMITING LAMINA , 2006, Retina.

[34]  G. Virgili,et al.  Laser photocoagulation for choroidal neovascularisation in pathologic myopia. , 2005, The Cochrane database of systematic reviews.

[35]  J. Holladay,et al.  Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.

[36]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[37]  M. Mochizuki,et al.  Myopic choroidal neovascularization: a 10-year follow-up. , 2003, Ophthalmology.

[38]  Jennifer I. Lim,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. , 2003, Ophthalmology.

[39]  Matthew A. Thomas,et al.  Subretinal surgery for choroidal neovascularization in patients with high myopia. , 2000, Archives of ophthalmology.

[40]  Rishi P. Singh,et al.  A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific. , 2019, Ophthalmology. Retina.

[41]  Paul Mitchell,et al.  Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. , 2014, American journal of ophthalmology.

[42]  M. Mochizuki,et al.  Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. , 2011, American journal of ophthalmology.

[43]  George A. Williams,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. , 2001, Ophthalmology.